EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of the prevalence of MASLD, MASH and liver fibrosis in a Dutch bariatric cohort

Willy Theel iD, Willem-Pieter Brouwer, Elisabeth van Rossum, Jan Apers, Susan Ter Borg, Tessa Noordermeer, Manuel Castro Cabezas

PLOS One · 24.06.2025 · 20 (6) · e0324813

DOI: 10.1371/journal.pone.0324813 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 24.06.2025. Verfasst von Willy Theel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal medicine, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Liver Cirrhosis, Bariatric Surgery, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) in bariatric populations has been widely studied but may vary geographically. This study evaluates MASLD/MASH prevalence and the utility of non-invasive tests (NITs) for liver fibrosis in a Dutch bariatric surgery cohort.

Methods

This single-center cross-sectional diagnostic accuracy study included 220 patients undergoing bariatric surgery. At baseline, 10 NITs were performed. Patients with liver stiffness measurements ≥ 8kPa using vibration-controlled transient elastography underwent a liver biopsy during surgery. Histology was assessed using the nonalcoholic fatty liver disease Activity Score. Diagnostic accuracy of NITs was evaluated against histology using sensitivity, specificity, and area under the receiver operating characteristic (AUROC). MASH was defined as steatosis with lobular inflammation and ballooning, with or without fibrosis. At-risk MASH included fibrosis ≥F2.

Results

Out of 77 patients (35%) eligible for histological analysis, the findings revealed a MASLD prevalence of 50.6%, MASH prevalence of 5.3%, and at-risk MASH prevalence of 2.6%. Most patients had no fibrosis (67.1%), while others exhibited mild fibrosis (F1: 23.7%, F2: 9.2%). Capped MAF-5 effectively identified fibrosis stage ≥2 (AUROC: 0.809), surpassing FIB-4 (AUROC: 0.645). Both the FAST score and capped MAF-5 demonstrated strong performance in detecting at-risk MASH.

Conclusion

MASLD/MASH prevalence and advanced fibrosis were lower than expected in this Dutch cohort. Capped MAF-5 demonstrated superior performance for fibrosis detection, while transient elastography and FIB-4 were less reliable. Further studies are needed to optimize NIT selection in bariatric populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisBariatric SurgeryFatty LiverNon-alcoholic Fatty Liver DiseaseHumansFemaleMalePrevalenceNetherlandsMiddle AgedAdultCross-Sectional StudiesElasticity Imaging TechniquesLiverCohort StudiesROC Curve

Autor:innen und Institutionen

  • Department of Internal medicine, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands.
  • Obesity Center CGG, Rotterdam, the Netherlands.
  • Department of Internal medicine, division of endocrinology, Erasmus MC, University Medical Center, Rotterdam, Rotterdam, the Netherlands.
  • Department of Gastroenterology & Hepatology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
  • Department of bariatric surgery, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands.
  • Department of Pathology, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands.

ORCID-Profile: Willy Theel

Zitieren

APA

Theel, W., Brouwer, W. P., van Rossum, E., Apers, J., Ter Borg, S., Noordermeer, T., & Castro Cabezas, M. (2025). Evaluation of the prevalence of MASLD, MASH and liver fibrosis in a Dutch bariatric cohort. PLOS One, 20(6), e0324813. https://doi.org/10.1371/journal.pone.0324813

Vancouver

Theel W, Brouwer WP, van Rossum E, Apers J, Ter Borg S, Noordermeer T, et al. Evaluation of the prevalence of MASLD, MASH and liver fibrosis in a Dutch bariatric cohort. PLOS One. 2025;20(6):e0324813. doi:10.1371/journal.pone.0324813

BibTeX
@article{Theel2025,
  author = {Theel, Willy and Brouwer, Willem-Pieter and van Rossum, Elisabeth and Apers, Jan and Ter Borg, Susan and Noordermeer, Tessa and Castro Cabezas, Manuel},
  title = {Evaluation of the prevalence of MASLD, MASH and liver fibrosis in a Dutch bariatric cohort},
  journal = {PLOS One},
  year = {2025},
  volume = {20},
  number = {6},
  pages = {e0324813},
  doi = {10.1371/journal.pone.0324813}
}
Kostenlos starten →